Abstract
The incidence of mucormycosis, defined as systemic infection caused by fungi of the class Phycomycetes has been increasing over the past 2 decades, especially in profoundly immunocompromised hosts. We report a new case in a patient presenting with post-transplant high-grade non-Hodgkin's lymphoma who received a prolonged treatment with voriconazole and caspofungin for an invasive pulmonary aspergillosis. Definite diagnosis of mucormycosis was made by liver biopsy of nodules mimicking progressive lymphoma. The patient died 1 week after the diagnosis of mucormycosis despite the administration of liposomal amphotericin B. The role of voriconazole and caspofungin in the emergence of mucormycosis is discussed.
MeSH terms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Aspergillosis, Allergic Bronchopulmonary / complications*
-
Aspergillosis, Allergic Bronchopulmonary / drug therapy
-
Aspergillosis, Allergic Bronchopulmonary / etiology
-
Caspofungin
-
Echinocandins
-
Fatal Outcome
-
Female
-
Humans
-
Kidney Transplantation / adverse effects*
-
Lipopeptides
-
Lymphoma, Non-Hodgkin / complications*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / etiology
-
Middle Aged
-
Mucormycosis / diagnosis
-
Mucormycosis / drug therapy
-
Mucormycosis / etiology*
-
Peptides, Cyclic / adverse effects
-
Pyrimidines / adverse effects
-
Treatment Failure
-
Triazoles / adverse effects
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Caspofungin
-
Voriconazole